Debt-to-EBITDA measures a company's ability to pay off its debt.
Syneos Health's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2022 was $64 Mil. Syneos Health's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2022 was $3,043 Mil. Syneos Health's annualized EBITDA for the quarter that ended in Jun. 2022 was $732 Mil.
Syneos Health's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2022 was 4.24.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Syneos Health's Debt-to-EBITDA or its related term are showing as below:
SYNH'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 2.42 Med: 6.14 Max: 22.82
Current: 4.54
During the past 11 years, the highest Debt-to-EBITDA Ratio of Syneos Health was 22.82. The lowest was 2.42. And the median was 6.14.
SYNH's Debt-to-EBITDA is ranked worse than 84.13% of 126
companies
in the Medical Diagnostics & Research industry
Industry Median: 1.25
vs SYNH: 4.54
Syneos Health Debt-to-EBITDA Historical Data
The historical data trend for Syneos Health's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Syneos Health Annual Data
Trend
Dec12
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Debt-to-EBITDA
22.82
6.13
6.16
6.22
4.89
Syneos Health Quarterly Data
Sep17
Dec17
Mar18
Jun18
Sep18
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Debt-to-EBITDA
6.03
4.62
3.91
6.10
4.25
Competitive Comparison
For the Diagnostics & Research subindustry, Syneos Health's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Syneos Health Debt-to-EBITDA Distribution
For the Medical Diagnostics & Research industry and Healthcare sector, Syneos Health's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Syneos Health's Debt-to-EBITDA falls into.
Syneos Health Debt-to-EBITDA Calculation
Debt-to-EBITDA measures a company's ability to pay off its debt.
Syneos Health's Debt-to-EBITDA for the fiscal year that ended in Dec. 2021 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2022) EBITDA data.
Syneos Health (NAS:SYNH) Debt-to-EBITDA Explanation
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Syneos Health Debt-to-EBITDA Related Terms
Thank you for viewing the detailed overview of Syneos Health's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Syneos is a global contract research and outsourced commercialization organization that provides services to pharmaceutical and biotechnology firms. Its clinical solutions segment offers early- to late-stage clinical trial support that ranges from specialized staffing models to strategic partnerships that oversee nearly all aspects of a drug program, while the company's commercialization solutions includes outsourced sales, consulting, public relations, and advertising services.
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
0.5(0.74%) Volume: 652,790 4:00PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NAS:SYNH has been successfully added to your 
